1096770-84-1

1096770-84-1 structure

Name: S32826
Chemical Name: S32826 disodium salt hydrate
CAS Number: 1096770-84-1
Molecular Formula: C₂₁H₃₆NO₄P
Molecular Weight: 397.49
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
Create Date: 2017-04-07 17:17:07
Modify Date: 2024-01-06 02:00:20
S32826 is a potent autotaxin inhibitor, with an IC50 of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes[1].

Name	S32826 disodium salt hydrate
Synonyms	[4-(Tetradecanoylamino)benzyl]phosphonic acid Phosphonic acid, [[4-[(1-oxotetradecyl)amino]phenyl]methyl]- [4-(Tetradecanoylamino)benzyl]phosphonic acid disodium salt hydrate [4-(tetradecanoylamino)phenyl]methylphosphonic acid

Description	S32826 is a potent autotaxin inhibitor, with an IC50 of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology
Target	Autotaxin:8.8 nM (IC50)
In Vitro	S32826 (0.001-10 μM; 10 days) dose-dependently inhibits the release of lyso-phosphatidic acid (LPA) by 3T3-F442A adipocytes with an IC50 of 90 nM and a maximal inhibition of 80% at 500 nM[1]. S32826 (1 μM; 24 h) inhibits Dexamethasone-induced increases in autotaxin (ATX) mRNA expression in HTM cells and lysoPLD activity in conditioned media. S32826 inhibits Dexamethasone-induced the phosphorylation of MLC and cofilin, mRNA upregulation of COL1A1 and COL4A1, and expression of α-SMA, fibronectin and collagen-1 in the HTM cells[2].
In Vivo	Topical application of S32826 (2-10 mM; 2 h-5 d) decreases intraocular pressure (IOP) in a dose- and time-dependent manner in rabbits[2]. S32826 (∼2 µM; single intracameral injection) reduces the IOP in rabbits, with the ocular hypotensive response lasting for more than 48 hrs[2]. S32826 (10 mg/kg; p.o., i.p., s.c., and i.v.) shows poor in vivo stability and/or bioavailability[1].
References	[1]. Ferry G, et, al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008 Dec;327(3):809-19. [2]. Honjo M, et, al. Role of the Autotaxin-LPA Pathway in Dexamethasone-Induced Fibrotic Responses and Extracellular Matrix Production in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):21-30. [3]. Iyer P, et, al. Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One. 2012;7(8):e42627.

Density	1.1±0.1 g/cm3
Molecular Formula	C₂₁H₃₆NO₄P
Molecular Weight	397.49
Exact Mass	397.238190
PSA	96.44000
LogP	5.00
Index of Refraction	1.536

Hazard Codes	Xi

1103672-42-9

1096770-84-1

Literature: Jiang, Guowei; Madan, Damian; Prestwich, Glenn D. Bioorganic and Medicinal Chemistry Letters, 2011 , vol. 21, # 17 p. 5098 - 5101

20074-79-7

1096770-84-1

Literature: Jiang, Guowei; Madan, Damian; Prestwich, Glenn D. Bioorganic and Medicinal Chemistry Letters, 2011 , vol. 21, # 17 p. 5098 - 5101

112-64-1

1096770-84-1

Literature: Jiang, Guowei; Madan, Damian; Prestwich, Glenn D. Bioorganic and Medicinal Chemistry Letters, 2011 , vol. 21, # 17 p. 5098 - 5101

Precursor 3
1103672-42-9 20074-79-7 112-64-1
DownStream 0

1103672-43-0	865704-62-7
873893-96-0	622852-35-1
1001334-19-5	825615-32-5
19789-09-4	1799952-48-9
101622-02-0	233772-38-8